Claims for Patent: 9,737,488

Summary for Patent: 9,737,488

Title:	Pharmaceutical composition for the treatment of cancer
Abstract:	The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.
Inventor(s):	Schuckler; Fritz (Bergisch Gladbach, DE), Wollenschlager; Axel (Bergisch Gladbach, DE)
Assignee:	Bayer HealthCare LLC (Whippany, NJ)
Application Number:	11/885,930
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,737,488
Patent Claims:	1. A pharmaceutical composition which is a tablet comprising: the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide as active agent in a portion of at least 55%, a filler in a portion of from 3 to 20%, a disintegrant in a portion of from 5 to 12%, a binder in a portion of from 0.5 to 8.0%, a lubricant in a portion of 0.2 to 0.8% and a surfactant in a portion of from 0.1 to 2% by weight of the composition. 2. The pharmaceutical composition of claim 1 comprising microcrystalline cellulose as a filler in a portion of from 3 to 20%, croscarmellose sodium as a disintegrant in a portion of from 5 to 12%, hypromellose as a binder in a portion of from 0.5 to 8.0%, magnesium stearate as a lubricant in a portion of from 0.2 to 0.8% and sodium lauryl sulfate as a surfactant in a portion of from 0.1 to 2% by weight of the composition. 3. The pharmaceutical composition of claim 1 wherein the composition is a solid oral dosage form. 4. The pharmaceutical composition of claim 1 wherein the composition is an immediate release tablet. 5. The pharmaceutical composition of claim 1 wherein the active agent is micronized. 6. The pharmaceutical composition of claim 5 wherein the micronized form has a mean particle size of from 0.5 to 10 microns. 7. The pharmaceutical composition of claim 1 further comprising water in an amount of less than or equal to 6% by weight of the composition. 8. The pharmaceutical composition according to claim 1 further comprising one or more cytotoxic agents, signal transduction inhibitors, or other anti-cancer agents, as well as with admixtures and combinations thereof. 9. The pharmaceutical composition of claim 1 showing a hardness of more than 80 N. 10. The pharmaceutical composition of claim 1 which is an oval tablet with a longest dimension of less than or equal to 25 mm. 11. The pharmaceutical composition of claim 1 which is a round tablet with a diameter of less than or equal to 13 mm. 12. The pharmaceutical composition of claim 1 wherein the amount of the active ingredient is from 54 mg to 1096 mg. 13. A pharmaceutical composition which is a tablet comprising: the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide as active agent in a portion of at least 55% a filler in a portion of 3 to 20% , a disintegrant in a portion of 5 to 12% and a binder in a portion of 0.5 to 8.0% by weight of the composition. 14. The pharmaceutical composition of claim 13 wherein the pharmaceutically acceptable excipient comprises microcrystalline cellulose as a filler, croscarmellose sodium as a disintegrant and hypromellose as a binder. 15. The pharmaceutical composition of claim 14 which additionally comprises magnesium stearate as a lubricant in a portion of 0.2 to 0.8%. by weight of the composition. 16. The pharmaceutical composition of claim 15 which additionally comprises sodium lauryl sulfate as a surfactant in a portion of 0.1 to 2% by weight of the composition. 17. The pharmaceutical composition of claim 13 wherein the composition is a solid oral dosage form. 18. The pharmaceutical composition of claim 13 wherein the composition is an immediate release tablet. 19. The pharmaceutical composition of claim 13 wherein the active agent is micronized. 20. The pharmaceutical composition of claim 19 wherein the micronized form has a mean particle size of from 0.5 to 10 microns. 21. The pharmaceutical composition of claim 13 further comprising water in an amount of less than or equal to 6%. 22. The pharmaceutical composition according to claim 13 further comprising one or more cytotoxic agents, signal transduction inhibitors, or other anti-cancer agents, as well as with admixtures and combinations thereof. 23. The pharmaceutical composition of claim 13 which is an oval tablet with a longest dimension of less than or equal to 25 mm. 24. The pharmaceutical composition of claim 13 which is a round tablet with a diameter of less than or equal to 13 mm. 25. The pharmaceutical composition of claim 13 wherein the amount of the active ingredient is from 54 mg to 1096 mg. 26. The pharmaceutical composition of claim 13 which additionally comprises a lubricant in a portion of 0.2 to 0.8% by weight of the composition and optionally a surfactant in a portion of 0.1 to 2% by weight of the composition. 27. A process for manufacturing the pharmaceutical composition according to claim 13 wherein the active agent is blended with at least one pharmaceutically acceptable excipient which is a filler, a disintegrant, a binder, a lubricant or a surfactant. 28. The process of claim 27 wherein: a) the active agent and at least one pharmaceutically acceptable excipient are wet granulated; b) the granulate is blended with the lubricant and optionally with one or more further pharmaceutically acceptable excipient; c) the post blend granulate is subdivided into single units and d) the product of step c) is optionally coated with one or more further pharmaceutically acceptable excipients. 29. The process of claim 28 wherein the product of step c) is coated with one or more further pharmaceutically acceptable excipients. 30. The process of claim 27 wherein the active agent and at least one pharmaceutically acceptable excipient are blended without granulation and directly compressed to tablets. 31. The process of claim 27 wherein the active agent alone or the active agent and at least one pharmaceutically acceptable excipient are treated by a dry granulation method and then compressed to tablets. 32. A method for treating a mammalian hyper-proliferative disorder comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 13 to a mammal in need thereof. 33. A pharmaceutical composition which is an immediate release tablet comprising: the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide as active agent in a portion of at least 55% and a pharmaceutically acceptable excipient which comprises a filler, a disintegrant, a binder and a lubricant , wherein one or more of the following applies, said filler is in a portion of 3 to 20%, said disintegrant is in a portion of 5 to 12% , said binder is in a portion of 0.5 to 8.0% , or said lubricant is in a portion of 0.2 to 0.8% by weight of the composition. 34. The pharmaceutical composition of claim 33 which additionally comprises a surfactant in a portion of 0.1 to 2% by weight of the composition. 35. A pharmaceutical composition which is an immediate release tablet comprising: the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide as active agent in a portion of at least 55% and at least one pharmaceutically acceptable excipient wherein the pharmaceutically acceptable excipient comprises microcrystalline cellulose as a filler in a portion of 3 to 20% by weight of the composition, croscarmellose sodium as a disintegrant in a portion of 5 to 12% by weight of the composition, hypromellose as a binder in a portion of 0.5 to 8.0% by weight of the composition, or magnesium stearate as a lubricant in a portion of 0.2 to 0.8% by weight of the composition. 36. The pharmaceutical composition of claim 35 which additionally comprises sodium lauryl sulfate as a surfactant in a portion of 0.1 to 2% by weight of the composition. 37. A pharmaceutical composition which is an immediate release tablet -showing a hardness of more than 80 N comprising: the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide as active agent in a portion of at least 55% and at least one pharmaceutically acceptable excipient which is a filler in a portion of 3 to 20% , a disintegrant in a portion of 5 to 12% , a binder in a portion of 0.5 to 8.0% , a lubricant in a portion of 0.2 to 0.8% or a surfactant in a portion of 0.1 to 2% by weight of the composition. 38. A pharmaceutical composition which is an immediate release tablet comprising: the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide as active agent in a portion of at least 55% and on microcrystalline cellulose as filler in a portion of 3 to 20% by weight of the composition. 39. The pharmaceutical composition of claim 38 which additionally comprises crosscarmellose sodium as a disintegrant, and magnesium stearate as a lubricant. 40. An immediate release pharmaceutical composition comprising the active agent the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide in a portion of at least 40% by weight of the composition and at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is an immediate release tablet. 41. The immediate release pharmaceutical composition of claim 40 comprising the active agent in a portion of at least 55% by weight of the composition. 42. The immediate release pharmaceutical composition of claim 40 comprising the active agent in a portion of at least 75% by weight of the composition. 43. The immediate release pharmaceutical composition of claim 40 wherein the active agent, the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide, is present in an amount of about 274 mg. 44. The immediate release pharmaceutical composition of claim 40 showing a hardness of more than 80 N. 45. The immediate release pharmaceutical composition of claim 43 showing a hardness of more than 80 N. 46. The immediate release pharmaceutical composition of claim 43 showing a hardness of more than 100 N. 47. The immediate release pharmaceutical composition of claim 40 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 48. The immediate release pharmaceutical composition of claim 43 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 49. The immediate release pharmaceutical composition of claim 44 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 50. The immediate release pharmaceutical composition of claim 45 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 51. The immediate release pharmaceutical composition of claim 46 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 52. The immediate release pharmaceutical composition of claim 40 wherein the at least one pharmaceutically acceptable excipient is one or more of microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate or sodium lauryl sulfate. 53. The immediate release pharmaceutical composition of claim 43 wherein the at least one pharmaceutically acceptable excipient is one or more of microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate or sodium lauryl sulfate. 54. The immediate release pharmaceutical composition of claim 40 wherein the at least one pharmaceutically acceptable excipient is one or more of a filler, disintegrant, binder, lubricant or surfactant. 55. The immediate release pharmaceutical composition of claim 43 wherein the at least one pharmaceutically acceptable excipient is one or more of a filler, disintegrant, binder, lubricant or surfactant. 56. The immediate release pharmaceutical composition of claim 55 comprising filler in a portion of from 3 to 20% by weight of the composition. 57. The immediate release pharmaceutical composition of claim 56 comprising microcrystalline cellulose as filler. 58. The immediate release pharmaceutical composition of claim 55 comprising disintegrant in a portion of from 5 to 12% by weight of the composition. 59. The immediate release pharmaceutical composition of claim 58 comprising croscarmellose sodium as disintegrant. 60. The immediate release pharmaceutical composition of claim 55 comprising binder in a portion of from 0.5 to 8.0% by weight of the composition. 61. The immediate release pharmaceutical composition of claim 60 comprising hypromellose as binder. 62. The immediate release pharmaceutical composition of claim 55 comprising lubricant in a portion of from 0.2 to 0.8% by weight of the composition as an excipient. 63. The immediate release pharmaceutical composition of claim 62 comprising magnesium stearate as lubricant. 64. The immediate release pharmaceutical composition of claim 55 comprising surfactant in a portion of from 0.1 to 2% by weight of the composition as an excipient. 65. The immediate release pharmaceutical composition of claim 64 comprising sodium lauryl sulfate as surfactant. 66. The immediate release pharmaceutical composition of claim 43 comprising a filler, disintegrant, binder and lubricant as excipients. 67. The immediate release pharmaceutical composition of claim 45 comprising a filler, disintegrant, binder and lubricant as excipients. 68. The immediate release pharmaceutical composition of claim 50 comprising a filler, disintegrant, binder and lubricant as excipients. 69. The immediate release pharmaceutical composition of claim 53 comprising a filler, disintegrant, binder and lubricant as excipients. 70. The immediate release pharmaceutical composition of claim 41 wherein the active agent, the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide, is present in an amount of about 274 mg. 71. The immediate release pharmaceutical composition of claim 70 showing a hardness of more than 80 N. 72. The immediate release pharmaceutical composition of claim 70 showing a hardness of more than 100 N. 73. The immediate release pharmaceutical composition of claim 70 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 74. The immediate release pharmaceutical composition of claim 71 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 75. The immediate release pharmaceutical composition of claim 42 wherein the active agent, the p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide, is present in an amount of about 274 mg. 76. The immediate release pharmaceutical composition of claim 75 showing a hardness of more than 80 N. 77. The immediate release pharmaceutical composition of claim 75 showing a hardness of more than 100 N. 78. The immediate release pharmaceutical composition of claim 75 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 79. The immediate release pharmaceutical composition of claim 76 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 80. An immediate release pharmaceutical composition comprising the active agent p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-car- boxylic acid methyl amide in an amount of about 274 mg and at least one pharmaceutically acceptable excipient wherein the pharmaceutical composition is an immediate release tablet showing a hardness of more than 80 N, which is either an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 81. The immediate release pharmaceutical composition of claim 80 showing a hardness of more than 100 N. 82. The immediate release pharmaceutical composition of claim 80 wherein the at least one pharmaceutically acceptable excipient is one or more of microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate or sodium lauryl sulfate. 83. The immediate release pharmaceutical composition of claim 80 wherein the at least one pharmaceutically acceptable excipient is one or more of a filler, disintegrant, binder, lubricant or surfactant. 84. The immediate release pharmaceutical composition of claim 72 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 85. The immediate release pharmaceutical composition of claim 77 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 86. The immediate release pharmaceutical composition of claim 40 showing a hardness of more than 100 N. 87. The immediate release pharmaceutical composition of claim 86 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 88. The immediate release pharmaceutical composition of claim 41 showing a hardness of more than 80 N. 89. The immediate release pharmaceutical composition of claim 41 showing a hardness of more than 100 N. 90. The immediate release pharmaceutical composition of claim 41 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 91. The immediate release pharmaceutical composition of claim 88 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 92. The immediate release pharmaceutical composition of claim 42 showing a hardness of more than 80 N. 93. The immediate release pharmaceutical composition of claim 42 showing a hardness of more than 100 N. 94. The immediate release pharmaceutical composition of claim 42 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 95. The immediate release pharmaceutical composition of claim 92 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 96. The immediate release pharmaceutical composition of claim 93 which is an oval tablet with a longest dimension of less than or equal to 25 mm or a round tablet with a diameter of less than or equal to 13 mm. 97. The immediate release pharmaceutical composition of claim 41 wherein the at least one pharmaceutically acceptable excipient is one or more of microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate or sodium lauryl sulfate. 98. The immediate release pharmaceutical composition of claim 42 wherein the at least one pharmaceutically acceptable excipient is one or more of microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate or sodium lauryl sulfate. 99. The immediate release pharmaceutical composition of claim 41 wherein the at least one pharmaceutically acceptable excipient is one or more of a filler, disintegrant, binder, lubricant or surfactant. 100. The immediate release pharmaceutical composition of claim 42 wherein the at least one pharmaceutically acceptable excipient is one or more of a filler, disintegrant, binder, lubricant or surfactant. 101. The immediate release pharmaceutical composition of claim 40 comprising a filler, disintegrant, binder and lubricant as excipients. 102. The immediate release pharmaceutical composition of claim 41 comprising a filler, disintegrant, binder and lubricant as excipients. 103. The immediate release pharmaceutical composition of claim 42 comprising a filler, disintegrant, binder and lubricant as excipients.